Articles Posted in FTC Antitrust Highlights

On December 29, 2008, the Federal Trade Commission (“FTC”) required a divestiture to resolve antitrust concerns with King Pharmaceuticals, Inc.’s (“King”) $1.6 billion acquisition of Alpharma, Inc. (“Alpharma”). To remedy the situation, the FTC is requiring King to divest Alpharma’s brand Kadian, an oral long-acting opioid (“LAO”) analgesic drug, to Actavis, one of the world’s…

On December 19, 2008, Teva Pharmaceuticals Industries Ltd.’s settled charges that its proposed $8.9 billion acquisition of rival generic drug maker Barr Pharmaceuticals Inc. would be anticompetitive. The consent order required Teva and Barr to sell assets in 29 relevant markets, including generic drugs commonly used to treat acid reflux disease, various types of cancer,…

On December 15, 2008, ESL Partners (“ESL”) of Greenwich, Conn., and ZAM Holdings (“ZAM”) of New York City, two investment funds with holdings in numerous companies, will pay $525,000 and $275,000, respectively, in civil penalties for violating antitrust pre-merger notification requirements under the Hart-Scott-Rodino Act of 1976 (“HSR Act”). According to the complaint, after its…

On November 25, 2008, the FTC moved to block a merger between CCC Information Systems Inc (“CCC”), a subsidiary of CCC Holdings Inc., and Mitchell International Inc (“Mitchell”), owned by Aurora Equity Fund III LP. Both companies provide services in estimatics, electronic systems used to estimate the cost of collision repairs, and total loss valuation…

On October 23, 2008, the Federal Trade Commission (“FTC”) challenged CCS Corporation’s (“CCS”) proposed $85 billion acquisition of Newpark Environmental Services (“Newpark”), a division of Newpark Resources, Inc. The FTC alleged that the proposed transaction would have combined two of only three providers of waste disposal services to the offshore oil and natural gas exploration…

On September 2, 2008, Marian R. Bruno, the Associate Director of Management and Operations in the Federal Trade Comission’s (“FTC”) Bureau of Competition (“Bureau”), was named the Deputy Director of the Bureau of Competition. Norman Armstrong, Deputy Assistant Director of the Bureau’s Mergers IV Division, has been named Acting Deputy Director. They join Kenneth Glazer,…

On August 13, 2008, the Federal Trade Commission (“FTC”) ordered Sun Pharmaceutical Industry Ltd (“Sun”) to sell all rights and assets of three distinct generic formulations of the anticonvulsant drug carbamazepine to Torrent Pharmaceutical Ltd, a generic drug company based in India, for its acquisition of Taro Pharmaceutical Industries Ltd. (“Taro”) to proceed. Sun, based…

On August 7, 2008, William E. Kovacic, the Federal Trade Commission Chairman, announced that Jeffery Schmidt, the Director of the Bureau of Competition for the past two and half years, will be leaving the FTC. Mr. Kovacic has named David P. Wales, the deputy director of the Bureau of Competition, as the Acting Director. Mr.…

On July 30, 2008, the Federal Trade Commission (“FTC”) entered into a settlement agreement that allows McCormick & Company Inc.’s (“McCormick”) proposed $605 million acquisition of Lawry’s and Adolph’s brands of seasoned salt products from Unilever N.V. (“Unilever”) to proceed. According to the FTC’s complaint, McCormick’s Season-All brand competes with Lawry’s brands in the manufacture…

On July 17, 2008, the Federal Trade Commission (“FTC”) issued a complaint challenging the proposed $9 billion acquisition of V&S Vin & Sprit (“V&S”), a wholly owned corporation of the Kingdom of Sweden, by Pernod Ricard (“Pernod”), a wholly owned subsidiary of France-based Pernod. The FTC contends that the transaction is anticompetitive and violates U.S.…